In agreement with this hypothesis, we observed in this study that NB1 cells are rather insensitive to both IGF1R inhibitors (GSK1904529A and linsitinib) employed in this study, with little effect on downstream AKT and ERK1/2 phosphorylation, suggesting that, in this NB cell line, the high expression levels of ALK may outcompete IGF1R in engagement of IRS2. The gene discussed is AKT1; the disease is neuroblastoma.